Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1618-7601
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations ; day:23 ; month:4 ; year:2020 ; pages:1-13
The European journal of health economics ; (23.4.2020), 1-13
- Urheber
-
Westerink, Lotte
Nicolai, Jelmer L. J.
Samuelsen, Carl
Smit, Hans J. M.
Postmus, Pieter E.
Griebsch, Ingolf
Postma, Maarten J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10198-020-01186-9
- URN
-
urn:nbn:de:101:1-2020070403584125938962
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Westerink, Lotte
- Nicolai, Jelmer L. J.
- Samuelsen, Carl
- Smit, Hans J. M.
- Postmus, Pieter E.
- Griebsch, Ingolf
- Postma, Maarten J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
AIH Therapy: Beyond First-Line
Tongue as a first-line immune organ?
Humoral First-Line Mucosal Innate Defence in vivo
Challenges to replace ACT as first-line drug
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Human scent as a first-line defense against disease
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Implementing Human Resource Management successfully: A first-line management challenge
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma
AIH Therapy: Beyond First-Line
Tongue as a first-line immune organ?
Humoral First-Line Mucosal Innate Defence in vivo
Challenges to replace ACT as first-line drug
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Human scent as a first-line defense against disease
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Implementing Human Resource Management successfully: A first-line management challenge
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma
AIH Therapy: Beyond First-Line
Tongue as a first-line immune organ?
Humoral First-Line Mucosal Innate Defence in vivo
Challenges to replace ACT as first-line drug
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Human scent as a first-line defense against disease
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Implementing Human Resource Management successfully: A first-line management challenge
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer